Zydus receives tentative approval from USFDA for Levomilnacipran Extended-Release Capsules
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).
The centre has initiated next generation sequencing (NGS) as a tool for undertaking studies on genomic epidemiology of pathogens
He urged the dignitaries to collaboratively work on the identified domains of improvement and make detailed reports on them
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, (RLD Toviaz®) had estimated annual sales of USD 177 million in the U.S. (IQVIA MAT September 2022).
Subscribe To Our Newsletter & Stay Updated